Production (Stage)
Turnstone Biologics Corp.
TSBX
$0.3329
-$0.0065-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Cost of Revenue | -10.29% | -40.12% | -36.36% | -45.88% | -64.59% |
| Gross Profit | 10.29% | -12.38% | -107.36% | -169.76% | -560.15% |
| SG&A Expenses | -12.93% | -8.16% | -1.30% | 0.55% | 6.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.18% | -3.29% | -0.39% | -8.59% | -17.23% |
| Operating Income | 20.18% | -29.72% | -61.79% | -72.60% | -561.85% |
| Income Before Tax | 16.11% | -27.60% | -43.51% | -46.13% | -314.58% |
| Income Tax Expenses | 112.23% | 112.94% | -808.49% | -2,671.43% | -582.05% |
| Earnings from Continuing Operations | 15.87% | -28.33% | -41.97% | -45.76% | -312.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.87% | -28.33% | -41.97% | -45.76% | -312.66% |
| EBIT | 20.18% | -29.72% | -61.79% | -72.60% | -561.85% |
| EBITDA | 19.58% | -33.06% | -69.06% | -82.32% | -859.16% |
| EPS Basic | 73.01% | 78.65% | 82.81% | 85.44% | 36.41% |
| Normalized Basic EPS | 72.43% | 65.34% | 70.48% | 78.54% | -192.07% |
| EPS Diluted | 73.01% | 78.65% | 82.81% | 85.44% | 36.74% |
| Normalized Diluted EPS | 72.43% | 65.34% | 70.48% | 78.54% | -135.66% |
| Average Basic Shares Outstanding | 39.40% | 100.47% | 258.10% | 690.08% | 533.95% |
| Average Diluted Shares Outstanding | 39.40% | 100.47% | 258.10% | 690.08% | 506.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |